替格瑞洛在氯吡格雷抵抗的急性STEMI患者中的有效性及安全性(3)
[4] Fuss B.Signaling pathways mediating adhesion and spreading through extracellular ADP and the P2Y12 receptor： presented by Maria P. Abbracchio[J]. Purinergic Signal， 2013，9(2)：131-133.
[5] Viviani Anselmi C， Briguori C， Roncarati R， et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease [J].JACC Cardiovasc Interv，2013，6(11)：1166-1175.
[6] Hobl EL， Derhaschnig U， Firbas C， et al.Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor[J].Eur J Clin Invest，2013，43(12)：1258-61.
[7] Goodman SG， Clare R， Pieper KS， et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor： insights from the platelet inhibition and patient outcomes trial. Circulation， 2012，125(8)：978-986.
[8] Wallentin L， Becker RC， Budaj A， et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med，2009，361(11)：1045-1057.
[9] Janssen PW， ten Berg JM.Platelet function testing and tailored antiplatelet therapy[J].J Cardiovasc Transl Res，2013，6(3)：316-328.
[10] Jneid H. The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline： a critical appraisal[J].Methodist Debakey Cardiovasc J，2012，8(3)：26-30.
(收稿日期：2015-02-15), 百拇医药(黄琼 袁义强 于力 毛幼林)
[5] Viviani Anselmi C， Briguori C， Roncarati R， et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease [J].JACC Cardiovasc Interv，2013，6(11)：1166-1175.
[6] Hobl EL， Derhaschnig U， Firbas C， et al.Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor[J].Eur J Clin Invest，2013，43(12)：1258-61.
[7] Goodman SG， Clare R， Pieper KS， et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor： insights from the platelet inhibition and patient outcomes trial. Circulation， 2012，125(8)：978-986.
[8] Wallentin L， Becker RC， Budaj A， et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med，2009，361(11)：1045-1057.
[9] Janssen PW， ten Berg JM.Platelet function testing and tailored antiplatelet therapy[J].J Cardiovasc Transl Res，2013，6(3)：316-328.
[10] Jneid H. The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline： a critical appraisal[J].Methodist Debakey Cardiovasc J，2012，8(3)：26-30.
(收稿日期：2015-02-15), 百拇医药(黄琼 袁义强 于力 毛幼林)